English

25 MAY
SÃO PAULO – SP - BRAZIL
(NOVOTEL MORUMBI)

PARTICIPANTS PROFILE

Product categories

Branded generics: 48.3%

Biological products: 43.3%

Biosimilars: 26.7%

Hospital products: 40.0%

Innovative medicines: 58.7%

more info




Partnering Strategy/Interests

In-licensing: 46.7%

Out-licensing: 40.0%

Co-marketing: 31.7%

Co-promotion: 26.7%

Co-development: 46.7%

more info




Therapeutic areas

Cardiovascular: 40.0%

CNS: 45.0%

Infectious diseases: 35.0%

Pain: 41.7%

Respiratory: 33.3%

more info



PARTICIPANTS 2016

Allergy/immunology: 17.5%

Cardiovascular: 40.0%

CNS: 45.0%

Dentistry: 5.0%

Dermatology: 15.0%

Drug delivers technol.: 20.0%

Gastroenterology: 19.2%

Gerontology: 11.7%

Gynecology: 18.3%

Infectious diseases: 35.0%

Hematology: 17.4%

Ophthalmology: 13.3%

Oncology: 24.2%

Orthopedics: 15.0%

Pain: 41.7%

Pediatrics: 15.0%

Psychiatrics: 17.5%

Respiratory: 33.3%

Rheumatology: 19.2%

Urology: 15.8%

Vaccines: 9.2%

partner